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Description

Pleomorphic dermal sarcoma (PDS) can clinically and histopathologically mimic atypical
fibroxanthoma (AFX). However, it has a more aggressive clinical course with a higher recurrence rate and metastatic potential. This case presentation aims to report a rapidly-growing, exophytic, 4 cm tumor following a non-diagnostic shave biopsy 2 months prior and to
highlight distinctive features between PDS and AFX needed to make the correct diagnosis.
Like AFX, PDS occurs on the sun-damaged skin of the elderly, usually on the head and neck.
Also, like AFX, PDS histopathologically consists of sheets or fascicles of epithelioid and/or
spindle-shaped cells, often with multinucleation, pleomorphism, and numerous mitotic figures. Immunohistochemistry cannot distinguish PDS from AFX but is used to exclude other
malignancies. PDS can be distinguished from AFX by size (PDS is usually >2.0 cm) and by
the presence of more aggressive histopathologic features, such as subcutaneous involvement, perineural and/or lymphovascular invasion, and necrosis. PDS is a rare entity not well
documented in the literature with confusing, misleading, and changing nomenclature. PDS is
a diagnosis of exclusion made after complete excision of the tumor with the aid of histopathology and immunohistochemistry.
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Introduction

Atypical fibroxanthoma (AFX) and pleomorphic
dermal sarcoma (PDS) can be indistinguishable by clinical appearance and histopathologic
findings on the initial biopsy.1 Distinguishing
between the two is essential, as the prognoses of these tumors are vastly different. AFX
follows a benign course, typically recurring only
after incomplete excision, and rarely metastasizes. PDS is more aggressive and has a higher
recurrence rate and metastatic potential. AFX
presents as a rapidly-growing, solitary papule
or nodule on sun-damaged, actinic skin of the
elderly, usually on the head and neck region.
PDS can have a similar presentation and should

be considered with larger tumors, particularly
when greater than 2.0 cm.2-4 Similar tumors
arising from the deep soft tissue and extending
into the skin should be designated as undifferentiated pleomorphic sarcoma (UPS). These
are high-grade soft tissue tumors with high
rates of recurrence and metastases.5 PDS has
also been designated "UPS of the skin," but
the use of this terminology should be avoided
as it may cause confusion among healthcare
providers.2,5
On biopsy, AFX and PDS (as well as UPS) are
pleomorphic tumors. They are diagnoses of
exclusion, requiring broad lineage-specific
immunohistochemical analysis to exclude other
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Figure 1. A 4.0 x 2.5 cm ulcerated, friable, exophytic mass presented on the left mid-frontal scalp
of an over 89-year-old Caucasian male.
poorly differentiated tumors such as squamous cell cancer and melanoma, among others.
Distinguishing these entities requires complete
excision to evaluate for aggressive features,
specifically the tumor's extent of invasion, with
AFX restricted to the dermis.6,7 We present this
case to increase awareness of this rare sarcoma, highlight its characteristic histopathologic
and immunophenotypic features, and emphasize the importance of complete excision of
tumors initially classified as AFX to prevent
mismanagement of an aggressive and potentially fatal tumor.

Case Presentation

An over 89-year-old Caucasian man with a
history of several non-melanoma skin cancers
presented with a 4.0 x 2.5 cm ulcerated, friable,
exophytic mass on the left mid-frontal scalp of
2 months duration (Figure 1).
The patient had previously presented 2 months
earlier with a non-healing scalp lesion. The
lesion was a 0.9 cm ulcerated, erythematous
papule at that time. Histopathology of a shave
biopsy was non-diagnostic and demonstrated
marked parakeratosis, fibrosing granulation
tissue in the upper dermis, with a heavy inflammatory infiltrate.
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A repeat biopsy of the exophytic mass was
performed for diagnostic and de-bulking
purposes. The histopathology of the re-biopsy
demonstrated an ulcerated tumor filling the
dermis. The tumor cells were pleomorphic,
spindled, and arranged in vague fascicles (Figure 2). The cytology was markedly atypical, with
large irregular nuclei, prominent nucleoli, and
numerous mitoses, including atypical forms
(Figure 3). An immunohistochemical analysis
was performed. The tumor cells were diffusely positive for CD10 and weakly positive for
CD68. Cytokeratin AE1/AE3, cytokeratin 5, p63,
S-100, MART-1, desmin, smooth muscle myosin,
CD31, and CD34 were all negative. While these
findings were consistent with AFX, complete
excision was recommended to exclude a more
aggressive process.
The patient subsequently underwent wide local
excision with 1-centimeter margins. The specimen showed atypical spindled cells extending
deep into the subcutaneous tissue (Figure 4).
Due to the depth of invasion and the subcutaneous tissue involvement, the lesion was diagnosed as PDS (previously diagnosed as UPS of
the skin). The margins were free of tumor. The
patient was referred to oncology for further
evaluation and consideration of adjuvant therapy. The patient and family declined the oncol-
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Figure 2. Histopathology hematoxylin and eosin stain of re-biopsy showed pleomorphic spindled
cells arranged in fascicles within the dermis.
ogy referral. At 4 months post-excision, there
was no evidence of tumor recurrence.

Discussion

Clinically, AFX can be indistinguishable from
PDS. However, they are vastly different. These

two diseases differ in clinical course and prognosis. A correct diagnosis is crucial to an optimal outcome. Both present as rapidly growing
solitary nodules, usually occurring on the head
and neck of sun-damaged skin of the elderly that frequently ulcerate, causing bleeding.1

Figure 3. A close-up view of hematoxylin and eosin stain showed atypical cytology, with large
irregular nuclei, prominent nucleoli, and numerous mitoses.
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Figure 4. Specimen of wide local excision specimen showed atypical spindled cells extending deep
into the subcutaneous tissue.
Ultraviolet (UV) exposure and previous radiation treatment are considered major risk
factors with these tumors since they have a
predilection for occurring on sun-exposed skin.
AFX is typically less than 2.0 cm in diameter,
located superficially within the dermis, and neither involves the subcutis nor invades deeper
structures such as the fascia or muscle.2-4 AFX
follows a benign course. The diagnosis of AFX
needs to be strictly defined so that it is not
grouped with other pleomorphic tumors of the
skin or deeply invasive sarcomas known to have
metastatic potential.5
The nomenclature of these entities has evolved.
Terms such as AFX, PDS, superficial UPS, UPS
of the skin, UPS, and malignant fibrous histiocytomas (MFH) have all been used to describe
this family of tumors, which share histopathologic and immunohistochemical features. With
advancements in immunohistochemistry, many
lesions previously called MFH have now been
reclassified into lineage-specific sarcomas, such
as liposarcoma, leiomyosarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, extraskeletal osteosarcoma, and sarcomatoid carcinoma. Malignant fibrous histiocytoma
is no longer considered a distinct entity.5
Histologically, AFX and PDS (and UPS) consist
of spindle-shaped cells arranged in sheets or
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a fascicular pattern and can exhibit multinucleation, pleomorphism, and mitotic figures.5
Immunohistochemically, these tumors often
have a strong expression for CD10, but this
marker lacks specificity. They are negative for
other lineage-specific markers, such as cytokeratins, S-100, CD31/CD34, and desmin/myosin,
allowing distinction from spindled squamous
cell carcinomas, melanoma, angiosarcoma, and
leiomyosarcoma, respectively.6,7
Tumors with AFX-like histopathology on biopsy
but are clinically greater than 2.0 cm centimeters in diameter should raise concern for
a more aggressive tumor. If the tumors have
a subcutaneous invasion, perineural invasion,
lymphovascular invasion, and/or necrosis, they
are best classified as PDS. UPS is a better designation if they arise from the deep soft tissue.
Our case illustrates the importance of recognizing this distinction, as the lesion was greater
than 2 cm, showed subcutaneous involvement
along with necrosis, and was negative for lineage-specific immunohistochemical stains. The
clinical course of beginning as a superficial papule suggests an origin in the skin rather than
deep soft tissues. PDS carries a more aggressive course, risk of recurrence, and metastatic
potential compared to AFX.8
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Arriving at the diagnosis of AFX or PDS can be
challenging and is one of exclusion. Both diagnoses require extensive immunohistochemical
panels to exclude other common pleomorphic tumors in the skin, such as melanoma,
squamous cell carcinoma, angiosarcoma, and
leiomyosarcoma.7,9,10 At a minimum, negative
staining for S-100/SOX10, cytokeratin, CD31/
CD34, and myosin/desmin should be confirmed
to exclude other diseases in the differential
diagnosis.7 The separation of AFX and PDS can
only be made with larger tumors and/or when
significant subcutaneous tissue is available for
analysis on complete excision, showing aggressive features such as invasion into the subcutaneous tissue, tumor necrosis, and/or perineural
or lymphovascular invasion.8 While it is known
that AFX is a rare tumor, the diagnosis of PDS
is even rarer, and its characteristics are less
documented in the literature.11,12
The distinction between AFX and PDS is vital
since they have similar clinical, histologic, and
immunohistochemical presentations, but their
behavior is vastly different. AFX follows a more
benign course with a reported infrequent local
recurrence rate, shown to be less than 5%, and
is most commonly associated with an incomplete removal.9,10,13 Evidence suggests an even
lower risk of recurrence when AFX is treated
with Mohs micrographic surgery.14 Most of the
reported cases of AFX with metastasis in the
literature were before the availability of immunohistochemistry. These were likely other pleomorphic malignancies and probably represent
misdiagnoses.6
In contrast, PDS behaves more aggressively
and recurs at a greater rate, along with greater
metastatic potential.8 The local recurrence rate
of PDS has been reported as 28%, and the risk
for metastasis is 10%.15 Despite the morphologic features of a high-grade sarcoma, the overall
disease course of PDS is more in line with that
of low-grade malignancy. Disease-related mortality is rare, but long-term clinical follow-up is
difficult to obtain due to the advanced age at
presentation and other comorbidities.8
Tumors designated as PDS, UPS of the skin,
superficial UPS, and a superficial variant of
MFH all likely represent the same entity as all
have similar clinical features with histopathologic characteristics of morphologically high-

grade tumors with a lack of lineage-specific
differentiation.16,17 PDS is the preferred term
as it causes less confusion. More importantly,
there is a distinction among PDS, AFX, UPS,
and MFH due to differences in clinical course
and prognosis.5,8,13,18

Conclusion

There is significant clinical and histopathologic overlap between AFX and PDS. However, if
present, the tumor's clinical size and aggressive histopathological features can help with
distinction. Tumors greater than 2.0 cm and/or
tumors with histopathologic features, such as
invasion of subcutaneous tissue, tumor necrosis, and perineural or lymphovascular invasion,
are best classified as PDS. These features are
consistent with its more aggressive course,
including recurrence and metastatic potential.
In our case, the lesion was a cutaneous, rapidly-growing, solitary tumor that was greater
than 2 cm and was on the sun-damaged scalp
of an elderly male. The immunohistochemical profile of the tumor showed a high-grade
pleomorphic sarcoma without specific lineage
differentiation. On excision, the subcutaneous
tissue was involved along with tumor necrosis,
leading to a diagnosis of PDS. The correct diagnosis ultimately required excision, histopathology, and immunohistochemistry.
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